Please login to the form below

Not currently logged in


This page shows the latest Tukysa news and features for those working in and with pharma, biotech and healthcare.

Seagen’s Tukysa granted NICE recommendation for breast cancer patients

Seagen’s Tukysa granted NICE recommendation for breast cancer patients

Seagen UK has announced that the National Institute for Health and Care Excellence (NICE) has issued a final appraisal determination, recommending Tukysa (tucatinib) as a combination treatment for patients with ... The combination treatment includes

Latest news

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Subscribe to our email news alerts


Add my company
Origins - The Patient Focused Specialists

Origins creates and delivers patient focused strategy, insights, data and solutions, which guides pharma and biotech companies to improve value...

Latest intelligence

The speed of science and the pace of comms
Pharma red tape slows comms but there is a solution, Paul Hutchings, founder of fox&cat, writes....
Improving cardiovascular disease care and awareness
Scott Curley talks to PME about the risks of CVD and the importance of getting the right treatment at the right time...
Virtual Patient Engagement Program: A Customer Story
Our client wanted to better understand the needs, preferences, and treatment gaps among adult patients with a rare genetic disease......